Johnson & Johnson announced today (November 24) that its COVID-19 vaccine was fully approved by Health Canada for individuals 18 and older. The approval follows data in a clinical study conducted by the pharmaceutical company that showed the single-shot vaccine was 75 percent effective at protecting people from severe or critical COVID-19. The efficacy data were collected about a month post-vaccination. Health Canada writes that the vaccine was 66 percent effective at protecting clinical trial participants in a government-led study where efficacy data were collected two weeks after vaccination.
Johnson & Johnson’s single shot was previously authorized in March 2021 in Canada under an interim order for emergency use in adults over 18 years of age. The shot has not yet received full approval in the United States.
See “Vector-Based Vaccines Come to the Fore in the COVID-19 Pandemic”
Earlier this year, the Johnson & Johnson vaccine...
Johnson & Johnson is the third COVID-19 vaccine to receive full approval from Health Canada, following the health agency's greenlight of Pfizer/BioNTech’s and Moderna’s double-dose vaccinations.
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
